Unraveling Monogenic Channelopathies and Their Implications for Complex Polygenic Disease  by Gargus, J. Jay
Am. J. Hum. Genet. 72:785–803, 2003
785
REVIEW ARTICLE
Unraveling Monogenic Channelopathies and Their Implications
for Complex Polygenic Disease
J. Jay Gargus
Department Physiology and Biophysics and Division of Human Genetics, Department of Pediatrics, University of California, Irvine
Ion channels are a large family of 1400 related proteins representing 11% of our genetic endowment; however,
ion-channel diseases reflect a relatively new category of inborn error. They were first recognized in 1989, with the
discovery of cystic fibrosis transmembrane conductance regulator, and rapidly advanced as positional and functional
studies converged in the dissection of components of the action potential of excitable tissues. Although it remains
true that diseases of excitable tissue still most clearly illustrate this family of disease, ion-channel disorders now
cover the gamut of medical disciplines, causing significant pathology in virtually every organ system, producing a
surprising range of often unanticipated symptoms, and providing valuable targets for pharmacological intervention.
Many of the features shared among the monogenic ion-channel diseases provide a general framework for formulating
a foundation for considering their intrinsically promising role in polygenic disease. Since an increasingly important
approach to the identification of genes underlying polygenic disease is to identify “functional candidates” within
a critical region and to test their disease association, it becomes increasingly important to appreciate how these
ion-channel mechanisms can be implicated in pathophysiology.
Introduction
Ion-channel diseases reflect a relatively new category of
inborn error. They were first recognized in 1989, with the
isolation of cystic fibrosis transmembrane conductance
regulator (CFTR [MIM 602421]) (Riordan et al. 1989),
then explosively advanced as positional and functional
studies converged in the dissection of components of the
action potential of excitable tissues. Although it remains
true that diseases of excitable tissue (nerve, muscle, and
heart) still most clearly illustrate this family of diseases,
ion-channel disorders now cover the gamut of medical
disciplines, causing significant pathology in virtually
every organ system, producing a surprising range of of-
ten unanticipated symptoms, and providing valuable tar-
gets for pharmacological intervention. Although there
have been a number of recent reviews on specific ion-
channel diseases, the intent of this review is not to cat-
alog new alleles or phenotypic variations for these syn-
dromes. It is, rather, to provide a general framework for
understanding monogenic channel diseases, highlighting
major themes common to these disorders across organ
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systems and formulating a foundation for considering
their intrinsically promising role in polygenic disease.
Ion Channels as Physiological Mechanisms
Ion channels are unique protein mechanisms that influ-
ence physiology in a fashion distinctly different from
enzymes. Ion channels carry out no biochemical trans-
formations. Product and substrate are inorganic ions and
differ only in regard to the side of themembrane onwhich
they reside. Their major function is the rapid conductive
transport of ions diffusing down their electrochemical
gradient, as if through a water-filled pore, and their ma-
jor design features are their mechanism of gating (how
they open and close this pathway) and their selectivity
(which ions are allowed access to the pathway). Both of
these features are now described in exquisite molecular
detail for at least a few prototypes (Doyle et al. 1998;
Morais-Cabral et al. 2001). However, the transported
ion itself is rarely of any physiological consequence: it
is the transmembrane currents and their contribution to
controlling the cell membrane potential that primarily
dictate physiology and create pathology. Since cells have
but one membrane potential, it is the great integrator in
signaling pathways and a natural substrate for summing
subtle polygenic abnormalities. Also—unlike biochem-
ical pathways, the overall flux of which is predominated
by a single rate-limiting step—membrane potential is
intrinsically a continuous variable fully reflecting subtle
changes in the entire host of contributing channels. Al-
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though a biochemical pathwaymay allow polygenic con-
trol points, this is largely idiosyncratic, whereas it is the
default for membrane potential.
Ion channels are a large family of related proteins
sharing features that have proven useful in identification
of their genes in the genome. For example, the large
superfamily of voltage-gated potassium channels shares
a monomer structure of six transmembrane helices and
a signature pore motif that forms the conductive path-
way (Hille 2001). The functional channel is a tetramer,
and the essence of potassium-channel function ismanifest
in the panoply of combinatorial heteromultimers formed
as monomers from family members coassemble, which
creates tremendous functional diversity. This diversity
conveys to them the modulating functions in signal pro-
cessing as they interact and “decide” the output. The
voltage-gated sodium and calcium channels are the “do-
ers” able to execute the result of signal processing, and,
although they can be perceived to share the structure
of the potassium channels, in their case, where a crisp
uniformity of channel function is required, a fixed pseu-
dotetramer structure is hardwired into the large endo-
duplicated genes that encode a pseudotetrameric func-
tional monomer. In addition to the major, a-channel
subunits that directly contribute to the conducting pore,
there is also a host of auxiliary subunits that modify
channel function. The human genome contains 1400
channel genes (GeneCards) representing 1%–2% of our
genetic endowment (Venter et al. 2001). The large num-
ber of channel genes does not reflect redundancy. Many
channel genes are expressed in a remarkably tissue-se-
lective fashion, whereas others, broadly expressed, pre-
dominate in the physiology of only a few tissues. Both
of these features allow channels to produce tissue-se-
lective disease and to offer highly selective targets for
therapeutic intervention. Since their job is not really the
movement of ions, but rather the shape of the electrical
signal they produce, physiology requires the diverse vo-
cabulary provided by multiple members of a gene fam-
ily. It is becoming increasingly clear that this gene-family
diversity is tremendously amplified again, not only
through combinatorial monomer assembly, but addi-
tionally through alternative splicing, allowing one chan-
nel locus to produce multiple splice isoforms and, hence,
multiple functionally distinct protein products. That na-
ture requires a genetic investment in this huge array of
subtly differing channels might lead one to expect that
subtle changes matter. Hence, it becomes less surprising
that pairs of diseases as apparently distinct as migraine
and ataxia or paralysis and myotonia—or even with
dominant versus recessive inheritance—are found to be
allelic. Again, that subtly differing alleles produce a
wide range of disparate phenotypes suggests the poten-
tial of this family of genes for contributing to polygenic
disease.
Patch electrode electrophysiology has been critical to
defining channel mechanisms, working hand-in-glove
with in vitro expression studies of cloned wild-type and
mutant channels (Noda et al. 1983; Hille 2001). Be-
cause of the magically tight (gigaohm) seal between the
patch electrode and cell membrane, the technique has
the sensitivity to monitor a single ion-channel molecule
in real time during its millisecond dance between con-
formations: “closed,” where it is nonconducting, and
“open,” where it passes on the order of 107 ions/sec,
producing a current of 1012 amps, a picoamp. For the
large family of voltage-gated channels, this transition is
induced by a change in the membrane potential. They
next spontaneously enter an “inactive,” nonconducting
conformation that is distinctly different from the closed
state, since while inactive, a channel cannot be opened.
Only by restoring the resting membrane potential does
the conformation become reset to the closed state that
has the potential to open.
Ion Channels as Mechanisms of Disease
The cardinal feature of ion-channel disease of excitable
tissues is a periodic disturbance of rhythmic function. In
the heart, this is manifest as a potentially fatal arrhyth-
mia; in skeletal muscle, as periodic alterations in con-
tractility, ranging from paralysis (the inability to contract)
to myotonia (the inability to relax); and, in the CNS, as
a seizure, ataxia, or migraine (table 1). The remarkable
finding is the absence of overt functional abnormality
the vast majority of the time. In the extreme, this results
in the tragic—but still very common—situation where
no phenotype is obvious until the moment of death.
Although many insights have been garnered as to how
a variety of stresses serve to create the decompensation
that allows these phenotypes to become manifest, the
mechanisms that compensate, in the long run, for a con-
stitutionally defective channel still largely remain to be
defined. Ion-channel phenotypes in nonexcitable tissues
are more diverse, altering signaling involved in endocrine
secretion (Thomas et al. 1995), the function of cytosolic
compartments (Kornak et al. 2001), and complex epi-
thelial secretory and resorptive functions, which, in the
kidney, produce secondary changes in systemic electro-
lyte balance and blood pressure (Hansson et al. 1995;
Simon et al. 1996). Although cystic fibrosis is historically
the first recognized genetic ion-channel disease, it re-
mains one of the least understood. Therefore, neither it
nor the other epithelial ion-channel diseases will be dis-
cussed further. They have, however, been recently re-
viewed (Lifton et al. 2001; Jentsch et al. 2002).
Didactically, it is most useful to begin with the cardiac
phenotype of arrhythmia and the Long QT (LQT) syn-
dromes, demonstrating how component parts of the
membrane potential are dissected by the genetic lesions
Table 1
Channelopathy Phenotypes
Phenotype and Disease Gene Pathogenic Mutationa
Cardiac arrhythmia:
LQT1 KCNQ1 Dominant negative, decrease IK
LQT2 KCNH2 Dominant negative and LOF, decrease IK
LQT3 SCN5A GOF slow inactivate, increase INa
Brugada syndrome SCN5A GOF short inactivation
LQT5 KCNE1 Dominant alter modulation, decrease IK
LQT6 KCNE2 Dominant alter modulation, decrease IK
LQT7b KCNJ2 Dominant negative, decrease IK
JLN/LQT1c KCNQ1 Recessive LOF, strong decrease IK
JLN/LQT5c KCNE1 Recessive LOF, strong decrease IK
Muscle weakness:
SCCMS CHRNA1 GOF increase activation, increase INa
SCCMS CHRNB1 GOF increase activation, increase INa
SCCMS CHRNE GOF increase activation, increase INa
Periodic paralysis:
HOKPPd CACNA1S Missense, alter E/C coupling
HOKPP SCN4A GOF decrease inactivation, increase INa
HOKPP KCNE3 Alter modulation, decrease IK
HYPPe SCN4A GOF decrease inactivation, increase INa
HYPPb KCNJ2 Dominant negative, decrease IK
Myotonia:
Paramyotonia SCN4A GOF decrease inactivation, increase INa
K-activated SCN4A GOF decrease inactivation, increase INa
Becker CLCN1 Recessive LOF, strong decrease ICl
Thomsen CLCN1 Dominant negative, decrease ICl
Malignant hyperthermia
MHS1 RYR1 Missense, alter E/C coupling
MHS2 SCN4A GOF decrease inactivation, increase INa
MHS5 CACNA1S Missense, alter E/C coupling
Seizures:
BFNC1 KCNQ2 Haploinsufficiency, decrease IK
BFNC2 KCNQ3 Haploinsufficiency, decrease IK
ADNFLE CHRNA4 GOF increase activation, increase INa
ADNFLE CHRNB2 GOF increase activation, increase INa
GEFS SCN1B GOF decrease inactivation, increase INa
GEFS SCN1A GOF decrease inactivation, increase INa
GEFS SCN2A GOF decrease inactivation, increase INa
GEFS GABRG2 Dominant missense, decrease ICl
JME GABRA1 Dominant missense, decrease ICl
JME CACNB4 Dominant missense, ICa
SMEI SCN1A Haploinsufficiency, decrease INa
…f KCNA1 Haploinsufficiency, decrease IK
…f CACNA1A Dominant negative, decrease ICa
Ataxia
…f CACNA1A Dominant negative, decrease ICa
SCA6 CACNA1A Dominant CAG expansion, decrease ICa
EA2 CACNA1A Haploinsufficiency, decrease ICa
EA1 KCNA1 Haploinsufficiency, decrease IK
Migraine:
FHM1 CACNA1A Dominant missense, decrease ICa
a E/Cp excitation/contraction; GOFp gain of function; LOFp loss of function;
ion currents are designated as IK, ICl, INa, and ICa.
b Phenotype includes Andersen syndrome.
c Phenotype includes deafness.
d Phenotype includes hypokalemia.
e Phenotype includes hyperkalemia.
f Single report; see text.
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Figure 1 Time correlation of EKG waves, ventricular myocyte
action potential, and the individual participating ion currents. a, EKG
trace, with each component wave labeled above, andQT interval, from
the start of the Q wave to the end of the T wave, indicated with
brackets. LQT syndrome prolongs this interval. b, Ventricular cardiac
myocyte action potential correlated in time with the EKG above. The
plateau phase of prolonged depolarization is indicated. By convention,
depolarization is an upward deflection from the baseline. c, Ion cur-
rents underlying myocyte action potential, correlated in time with the
EKG and action potential. Individual traces are shown for a pure
sodium, potassium, and calcium current, the sum of which produces
the action potential. Sodium and calcium channels produce depolar-
izing currents, reflected as an upward deflection. Potassium channels
produce a hyperpolarizing current, reflected as a downward deflection.
and how this creates a natural substrate for polygenic
interactions. It further provides specific paradigms for
how subunit interactions can be manifest; how loss-of-
function and gain-of-function phenotypes occur; and
how dominance can arise through either haploinsuffi-
ciency, gain-of-function, or in a “dominant-negative”
fashion. The muscle and CNS phenotypes, although not
lending themselves to as simple a “functional cartoon,”
are easily built by extrapolation from this substrate.
They further illustrate the power of gene families in
identifying candidate disease genes and reinforce the
intrinsic polygenic nature of such phenotypes.
The Cardiac Phenotype: Arrhythmia
Details of the LQT syndrome and its clinical management
have been recently reviewed (Towbin and Vatta 2001;
Marban 2002). There are twomajor LQT syndromes, the
Romano-Ward syndrome (RW [MIM 192500]), which
has dominant inheritance and a phenotype limited to the
heart, and the Jervell and Lange-Nielsen syndrome (JLN
[MIM 220400]), which has recessive inheritance and an
additional sensorineural hearing loss. LQT is a fatal ar-
rhythmia syndrome that, as the name suggests, prolongs
the QT interval measured on the electrocardiogram
(EKG). This is the long interval of the cardiac cycle dur-
ing which the ventricles repolarize; their depolarization
is reflected by the QRS waves (fig. 1a). A design feature
that is “engineered” into the ventricular action potential
by the mix of ion channels in its membrane is a pro-
longed plateau phase of depolarization, a phase not pre-
sent in the classic rapid action potential of nerve (fig.
1b). LQT syndrome is caused by mutations in these car-
diac ion channel genes (fig. 2). The plateau phase is a
time during which calcium enters myocytes to produce
contraction (fig. 1c, bottom), but, as importantly, the
plateau phase serves to hold sodium channels in the
“inactive” nonexcitable state until the depolarizingwave
has spread to all of the electrically coupled myocardium
(fig. 1c, top). In this manner, it can be assured that all
ventricular myocytes will repolarize and regain the abil-
ity to depolarize again in synchrony. If this mechanism
fails and asynchrony is initiated, an endlessly looping
futile depolarization wave spreads through any newly
excitable domains of the tissue. Such asynchrony is le-
thal, since, unless the entire ventricular muscle depolar-
izes and contracts together, it does not pump blood but
only fibrillates. As seen in figure 1, during the plateau
phase, there is a struggle between the depolarizing so-
dium and calcium currents and the repolarizing potas-
sium currents, with the potassium currents finally over-
coming the depolarizing currents and restoring the resting
membrane potential. Mutations that serve to enhance the
sodium current or to reduce the potassium currents pre-
dictably prolong the plateau and are associated with LQT
syndrome. This is a dangerous situation, since prolonging
this struggle opens the opportunity for asynchrony and
susceptibility to arrhythmia, as described above.
LQT mutations have now been found in six cardiac
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Figure 2 Ventricular cardiac myocyte action potential, showing the contribution of individual ion channels and gene products. The name
of the current is placed adjacent to the time at which it predominates in the action potential. Upward arrows indicate a depolarizing current;
downward arrows indicate a hyperpolarizing current. The name of the genes contributing the channel subunits are placed adjacent to the current
name. Each gene named has dominant alleles that produce the RW LQT syndrome. The two genes forming the IKs channel also have recessive
alleles producing the JLN LQT syndrome.
ion-channel genes, one encoding the cardiac sodium
channel and five encoding the primary and auxiliary sub-
units of three different potassium channels (fig. 2). Al-
though this provides a nearly complete dissection of the
major channels involved during the plateau phase, one
major actor, the cardiac calcium channel, encoded by
CACNA1C, has yet to yield a pathogenic allele. It is
unfortunate that nearly all of these mutations are rare,
“private” mutations, so routine genotypic diagnosis of
these disorders is still not practical, obviating postmor-
tem diagnosis. On the other hand, a careful reading of
an EKG QT interval, corrected for heart rate (QTc),
can make the diagnosis (Marban 2002). Despite this,
however, the disease is still not uncommonly diagnosed
only after repeated deaths in a family, with a majority
of patients being asymptomatic until death but having a
family history positive for undiagnosed symptoms or
deaths. There is a characteristic context of death observed
in the syndrome that further illuminates the critical bal-
ancing act performed by multiple cardiac channels in
normal physiology. The context is that of excess adre-
nergic outflow caused by high emotion or exertion. The
reason that this is a risk is that heart rate increases
dramatically in this “fight or flight” response, and, al-
though we may think about this in terms of the b ad-
renergic receptor increasing the rate at which the heart
depolarizes and contracts, it is clear that to depolarize
more rapidly, it must also repolarizemore rapidly. In fact,
specific cAMP-dependent channel regulatory mecha-
nisms assure this coordination, effectively shortening
the QT as the heart rate rises. However, in a patient
with an intrinsic defect that lengthens the QT, the ad-
justment cannot keep pace, and an arrhythmia ensues.
The Dominant LQT Genes
LQT1 (MIM 192500) was the first locus identified, pos-
itionally through linkage, that causes this syndrome (Keat-
ing et al. 1991). All of the other LQT genes were iden-
tified as functional candidates within a mapped interval.
LQT1 is located on chromosome 11p15.5, and, although
the Ras oncogene was initially considered to be the can-
didate, it was ultimately demonstrated that mutations in
a potassium-channel a subunit gene, KCNQ1, were
causal (Wang et al. 1996). Over 30 different pathogenic
alleles have been reported in this gene, and they are the
most common cause of RW syndrome. They primarily
confer a dominant-negative phenotype when studied in
vitro (Wollnik et al. 1997). Defective subunits coassem-
ble with wild-type copies, producing, through combi-
natorials, a supermajority of defective channel tetramers
and, hence, reduced current. Naturally occurring trun-
cated splice isoforms of this channel behave similarly
(Demolombe et al. 1998), suggesting that perhaps these
mutants are taking advantage of a native mechanism for
channel regulation. When expressed in vitro, KCNQ1
produces a current not recognizable in the heart; however,
when expressed together with its b subunit, encoded by
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KCNE1, they can be recognized to produce the IKs chan-
nel underlying the slow delayed rectifier K current that
participates in repolarization (fig. 2) (Barhanin et al.
1996).
LQT2 (MIM 152427) was the first LQT gene cloned,
taking advantage of a candidate gene approach within
the region of chromosome 7q35-36 where a second lo-
cus was identified in families not mapping to chromo-
some 11 (Curran et al. 1995). The gene, KCNH2, was
a strong functional candidate on the basis of its homology
to a fly gene with a proven ability to create a rhythm
disorder phenotype, ether-a-go-go (Warmke and Ga-
netzky 1994). Over a dozen alleles have been reported,
and, like KCNQ1, many confer a “dominant-negative”
phenotype when expressed in vitro. However, other dom-
inant alleles appear to be simple loss-of-function alleles,
suggesting that the membrane current via this channel is
so finely tuned that a haploinsufficiency mechanism is
adequate to produce dominance (Sanguinetti et al. 1996).
Also like KCNQ1, coexpression of KCNH2 with its b
subunit, KCNE2, produces a current that can be rec-
ognized in the heart, in this case IKr, the rapidly acti-
vating delayed rectifier K current (fig. 2) (Abbott et al.
1999).
The genes underlying LQT5 (MIM 176261) and
LQT6 (MIM 603796), two adjacent loci on chromo-
some 21q22.1, are precisely the two highly homologous
b subunits, KCNE1 and KCNE2, respectively, discussed
above. Both are proteins with only a single transmem-
brane alpha helix, and both function only to modify the
behavior of the a subunit with which they multimerize.
Dominant pathogenic alleles are missense and effec-
tively achieve dominance by altering channel gating to
produce less current (Splawski et al. 1997b; Abbott et
al. 1999).
LQT3 (MIM 603830) is caused by a qualitatively dif-
ferent mechanism from those producing decreased po-
tassium current discussed above. The etiology of this
disease is mutations in the SCN5A gene found at chro-
mosome 3p21-24 (Wang et al. 1995). It encodes a car-
diac-specific voltage-gated sodium channel that underlies
the rapid depolarization phase that produces the QRS
complex and ventricular contraction (fig. 1; fig. 2). Chan-
nels encoded by pathogenic alleles have delayed or de-
creased inactivation after opening, which leaves excess
inward depolarizing current during the plateau phase,
thus delaying the time at which potassium currents can
bring about repolarization. They are thus dominant
“gain-of-function” mutations (Bennett et al. 1995). A
distinct set of alleles producing the opposite effect on
inactivation, a rapid recovery from inactivation, pro-
duce a different dominant arrhythmia syndrome, Bru-
gada syndrome (MIM 601144) (Chen et al. 1998). The
myocardium of these individuals contains a mixed pop-
ulation of sodium channels that are no longer locked in
synchrony by a common period of inactivation, forming
an ideal substrate for arrhythmia. It is surprising that
some alleles are capable of producing either sodium-
channel phenotype in a family (Grant et al. 2002), dem-
onstrating the delicate balancing act between excitation
and inactivation carried out by the sodium channel and
hinting at modifier genes that alter this balance. Both
features point to the potential participation of ion-chan-
nel mechanisms in polygenic disorders.
Andersen syndrome (MIM 170390) is a dominant
multisystem disorder that includes long QT but also in-
cludes extra-cardiac findings, such as periodic paralysis
and, more surprising, dysmorphology (Sansone et al.
1997). Dominant-negative alleles of the potassium chan-
nel gene KCNJ2 are responsible for this syndrome,
sometimes referred to as LQT7 (MIM 600681) (Tris-
tani-Firouzi et al. 2002). The KCNJ2 channel subunits
multimerize to form the inwardly rectifying potassium
channel that governs the resting membrane potential of
the cardiac myocyte. Current through this channel par-
ticipates at the very end of repolarization, and, hence,
dominant-negative loss of its function prolongs the pro-
cess. The extra-cardiac findings imply that it contributes
in a significant way to membrane signaling in muscle
and perhaps in developmental processes underlying the
dysmorphology (Preisig-Muller et al. 2002).
The Recessive LQT Genes
JLN differs from RW syndrome in that inheritance is re-
cessive, and, although the cardiac arrhythmia phenotype
is intermittent just as in RW syndrome, there is a con-
stitutive sensorineural hearing loss. It is surprising that
the JLN alleles are strong loss-of-function or null alleles
in the same genes that cause dominant LQT1 and LQT5;
they are KCNQ1 (Splawski et al. 1997a) and KCNE1
(Duggal et al. 1998), the two channel genes encoding
the IKs channel (fig. 2). The channel is abundantly ex-
pressed in the inner ear, where it is involved in potas-
sium-rich endolymph production. Only complete loss of
the channel significantly disturbs this secretory process,
demonstrating that one mechanism to generate diverse
phenotypes with different alleles is to change function
such that the critical threshold in different tissues is
crossed by each. Although it is still quite unusual to find
dominant and recessive alleles in the same gene, as will
be discussed below, this is not uncommon in channel
diseases. It is also of note that another inner ear LQT1
homolog, encoded by KCNQ4, has alleles that produce
only deafness without LQT (DFNA2 [MIM 600101])
(Kubisch et al. 1999).
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The Prospects of Polygenic Cardiac Ion Channel
Syndromes
From the description above of the interactions between
the multiple cardiac ion channels in maintaining and
terminating the plateau phase of the cardiac action po-
tential, one can easily imagine how minor functional
variants in these same genes could sum with one another
to produce a major alteration in the plateau phase and,
hence, a polygenic LQT, arrhythmia, or sudden-death
phenotype. Although initial studies suggested that LQT
is a highly penetrant Mendelian phenotype readily diag-
nosed by EKG, it has more recently become clear that
there are both “weak” and “subclinical” alleles of these
genes and likely polygenic interactions.Additionally, there
is clearly an environmental component to the disease,
seen as a pharmacogenetic syndrome, that greatly broad-
ens the scope of the diseases involving these cardiac ion-
channel genes. These more subtle features of disease pro-
duced by the LQT genes became most apparent in
studies on families initially considered to have a case of
“sporadic” LQT (Priori et al. 1999). Whereas half of
these probands had the predicted new dominant mu-
tation in one of the LQT genes, the other half were found
not to have new mutations but, rather, to have families
segregating a weak pathogenic LQT allele. These fam-
ilies had many silent carriers with no EKG abnormality,
in generations both older and younger than the proband,
or they had carriers who only expressed the phenotype
after taking a medication with potassium-channel–
blocking activity. These silent carriers presumably lacked
a phenotype, because they lacked other unidentified sus-
ceptibility alleles at other loci carried by the proband.
The pharmacological induction of the phenotype in such
an individual suggests that environmental or genetic li-
ability can sum with that contributed by the weak LQT
alleles (Yang et al. 2002). Since the drugs that unmask
the phenotype produce known effects like those of LQT
mutations (K channel block), presumably so does the
unmasking genetic liability. The pharmacogenetic LQT
syndrome has become clinically important, since many
common medications can induce this potentially lethal
disorder. These include antihistamines (such as Seldane),
antibiotics, and cisapride, as well as the more predictable
antiarrhythmics (Towbin and Vatta 2001). Thus far, all
implicated drugs share a common mechanism of action
that involves the block of IKr potassium channels, and a
number of cases now explicitly demonstrate that weak
or subclinical alleles in the LQT genes, encoding both
Na and K channels, are contributory to the pharma-
cogenetic disease (Sesti et al. 2000; Makita et al. 2002;
Yang et al 2002).
A special consideration of pathogenic weak LQT al-
leles is raised by the contribution of these genes to sud-
den infant death syndrome (SIDS [MIM 272120]). In a
landmark prospective study spanning an 18-year period,
Schwartz and coworkers from nine large maternity hos-
pitals performed EKGs on all healthy newborns on the
3rd or 4th day of life, studying a total of 134,000 neo-
nates. They performed a 1-year follow-up evaluation and
observed that the infants who died of SIDS had a longer
QTc interval at birth than did survivors or infants dying
of other causes, even though none of their families had
a history positive for LQT (Schwartz et al. 1998). Fur-
ther, fully half of the infants dying of SIDS (12 of 24)
had a QTc at birth 12 SD above the mean for the cohort.
In a neonate, this finding alone predicts a 41-fold in-
crease in the odds of dying of SIDS (Schwartz et al.
1998). Such screening is controversial, however (Zu-
pancic et al. 2000; Schwartz 2001; Spooner et al. 2001).
Because SIDS is so rare, despite the finding’s dramatic
odds ratio, only 2% of the neonates found to have a
long QT die of SIDS. Therefore, the societal costs as-
sociated with saving one of those lives through universal
screening and treatment can be large. Studies are be-
ginning to add a molecular dimension to these cases of
neonates with a long QT and SIDS. In a few cases, a
new mutation in one of the LQT genes, producing an
allele previously seen in a family with the classical syn-
drome, can be identified (Schwartz et al. 2000, 2001).
It remains to be determined whether weak inherited
mutations or even polymorphisms in two or more of
the LQT genes contribute to the rest.
The Skeletal Muscle Phenotypes: Paralysis, Myotonia,
and Hyperthermia
For the purpose of this review, the key features that the
skeletal muscle ion-channel genes and phenotypes reveal
are, first, how essentially the same ion channels and even
the same types of mutations seen in the LQT syndrome
produce interpretable yet distinct phenotypes in this dif-
ferent tissue and, second, that a wide range of phenotypes
can be produced with allelic mutations in ion-channel
genes. Both aspects are likely to be critical in evaluating
the role of these mechanisms in polygenic disease phe-
notypes. For this reason, only those aspects of these dis-
eases will be covered here. There have, however, been
recent comprehensive reviews of the skeletal muscle ion-
channel disorders and their treatment (Jurkat-Rott et al.
2002). Most simply, there are two major skeletal muscle
phenotypes produced by ion-channel disorders, paralysis
and myotonia. The third, apparently quite different, phe-
notype, malignant hyperthermia, a potentially lethal phar-
macogenetic syndrome producing an anesthesia-induced
elevated body temperature, is surprisingly closely related.
The skeletal muscle action potential is in many ways
similar to the initial portion of that in heart (fig. 1). It is
a fast depolarization followed by a rapid repolarization,
much like that in nerve. Instead of arising endogenously
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within the tissue, as at the cardiac pacemaker in the
sinoatrial node, the inciting muscle depolarization ar-
rives via the synaptic release of acetylcholine from a
motor nerve terminal at the neuromuscular junction. A
ligand-gated cation channel, the heteropentameric nico-
tinic acetylcholine receptor (nAChR), brings about the
initial depolarization. Dominant gain-of-function mu-
tations in three of the five nAChR subunits, encoded by
CHRNA1, CHRNB1, andCHRNE, produce slow-chan-
nel congenital myasthenic syndrome (SCCMS [MIM
601462]), characterized by muscle weakness (Engel et al.
1998). Acetylcholine dissociates slowly from these mu-
tant receptors, leaving them persistently activated, de-
polarizing the membrane. In the physiological condition,
the tiny receptor-mediated membrane depolarization
opens a few sodium channels, further depolarizing the
membrane, causing more sodium channels to open in a
reinforcing cycle until all sodium channels have explo-
sively opened, spreading a rapid depolarizing wave
across the surface of the muscle. At this point, all of
the sodium channels are rendered “inactive” and no-
nexcitable, beginning the process of repolarization, a
process completed when other channels restore the rest-
ing potential and return the sodium channels to the
“closed” state. The major subunit of these sodium chan-
nels is the muscle-specific isoform a4, encoded by
SCN4A, a relative of the gene involved in LQT3. Alleles
in this gene produce a diverse array of muscle pheno-
types; they will be discussed below.
As the muscle depolarization reaches the T-tubules–
specialized membrane invaginations to facilitate activa-
tion of contraction throughout the large muscle fiber, it
activates the voltage-gated calcium channel, which is
similar in structure to the sodium channel discussed
above. The major, a1, subunit is pseudotetrameric and
contains the ion-conducting pore. Missense alleles give
rise to one type of the complicated phenotype hypo-
kalemic periodic paralysis (HOKPP [MIM 170400])
(Ptacek et al. 1994), discussed below. Its function is
modified by auxiliary b, g, and a2/d subunits, the skel-
etal muscle isoforms being encoded by CACNA1S,
CACNB1, CACNG1, and CACNA2D1, respectively
(Jurkat-Rott et al. 2002). This channel is responsible for
rapidly immersing the contractile proteins throughout
the large muscle cell in elevated concentrations of ionic
calcium to bring about concerted contraction. It does this
in part by allowing the passage of extracellular calcium
through its pore, down its electrochemical gradient into
the cytoplasm. But, additionally, a large cytosolic loop
in the a1 subunit contacts a different calcium channel
located in a closely opposed different membrane com-
partment, the calcium-rich sarcoplasmic reticulum (SR).
Through this physical connection, the voltage-gated
channel directly gates the SR calcium release channel,
called the “ryanodine receptor” (encoded by RYR1),
opening it and spilling the intracellular calcium stores
into the cytoplasm (Tanabe et al. 1988). Missense alleles
altering either the loop of the a1 subunit (Monnier et al.
1997) or its contact domains on the ryanodine receptor
(Quane et al. 1993) (MHS5 [MIM 601887] and MHS1
[MIM 145600], respectively) render this complex hy-
persensitive to general anesthetics, such as halothane,
triggering massive calcium release, muscle activation, and
malignant hyperthermia. In the physiological condition,
after opening, both the sodium and calcium channels
spontaneously enter the nonconducting “inactive” con-
formation, beginning the process of membrane repo-
larization, a process completed by potassium channels
that hyperpolarize the membrane, resetting the sodium
and calcium channels into the “closed” conformation.
Mutations in one of these potassium channel subunits,
encoded by KCNE3, a relative of the LQT5 and LQT6
genes, have recently been shown to be one of the causes
of HOKPP (Abbott et al. 2001), rendering every mem-
ber of this KCNE gene family the site of a pathogenic
mutation. The sodium and calcium channels then are
kept closed by the large stabilizing current of the chlo-
ride channels, encoded by CLCN1, and both dominant
and recessive allelic mutations that inactivate this chan-
nel produce myotonia-repeated muscle contractions,
since, if the stabilization fails, repetitive cycles of sodium
channel activation occur. The recessive loss-of-function
alleles produce Becker myotonia (MIM 255700), with
a phenotype characterized by stiffness and paradoxi-
cally weak hypertrophied muscles; the dominant-neg-
ative alleles leave more residual current and produce
Thomsen myotonia (MIM 160800), which has a similar
but milder phenotype without weakness (Meyer-Kleine
et al. 1995).
Recognizing how these ion-channel disorders are
manifest in the heart and muscle should help us un-
derstand, and perhaps predict, additional ion-channel
disorders in these and other tissues. Once mutations are
found in one ion-channel family member, the other
family members are suspicious characters (table 2). For
example, additional sodium-channel a subunit genes
SCN1A and SCN2A have recently been recognized as
seizure loci, as have additional KCNQ potassium-chan-
nel subunit genes KCNQ2 and KCNQ3. Further, one
can gain insight into probable mechanisms of action of
these mutations on the basis of those previously seen in
other family members.
Another insight best illustrated by the skeletal muscle
sodium-channel lesions is the superficial diversity of
clinical syndromes that can be produced by very subtle
“tweaks” in channel function: clinically, nothing looks
more different from paralysis than myotonia, but, com-
monly, a given patient can move from one state to the
other. If one were forced to consider that the diseases
were allelic, one might guess that the former was caused
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Table 2
Channelopathy Gene Families
Gene Family Tissue Disease Phenotype Pathogenic Mutation
KCNE1 Heart/ear LQT5/JLN Dominant negative/recessive loss of function
KCNE2 (100%) Heart LQT6 Dominant negative
KCNE3 Muscle HOKPP Dominant negative
KCNQ1 Heart/ear LQT1/JLN Dominant negative/recessive loss of function
KCNQ2 CNS BFNC1 Dominant loss of function
KCNQ3 (80%) CNS BFNC2 Dominant loss of function
KCNQ4 Ear DFNA2 Dominant missense
KCNQ5 CNS 6q14
RYR
RYR1 Muscle MHS1 Missense
RYR2 (66%) Heart Ventricular tachycardia Missense
RYR3 CNS 15q14
SCN1A CNS GEFS/SMEI Gain of function/loss of function
SCN2A CNS GEFS Gain of function
SCN3A CNS 2q24
SCN4A (40%) Muscle HYPP/HOKPP/MHS/etc. Gain of function
SCN5A Heart LQT3/Brugada S Gain of function
SCN6A and SCN7A Neuronal 2q23
SCN8A Motor endplate 12q13
SCN9A Neuroendo 2q24
SCN10A Nerve/muscle 3p22
SCN11A and SCN12A Sensory neurons 3p24
SCN1B CNS GEFS Gain of function
SCN2B Neuronal 11q23
CACNA1S Muscle HOKPP/MHS5 Missense
CACNA1A CNS FHM1/EA2/SCA6/seizures Many types
CACNA1F Retina Night blindness Hemizygous loss of function
CHRNA1 Muscle SCCMS Gain of function
CHRNA4 CNS ADNFLE Gain of function
CHRNB1 Muscle SCCMS Gain of function
CHRNB2 CNS ADNFLE Gain of function
CHRNE Muscle SCCMS Gain of function
NOTE.—Gene families ranked according to the percent of family members with proven disease association. Percent of
members with proven association given in parentheses. Chromosome location is given for members yet to be associated
with disease. Only the known pathogenic members are listed for large families having only a few known pathogenicmembers.
by hypomorphs and the latter by hypermorphs. How-
ever, all of the muscle sodium-channel alleles appear to
share with the cardiac sodium-channel LQT3 alleles
delayed incomplete inactivation as their mechanism of
pathogenesis. The range of phenotypes such a lesion in
this gene can produce include:
1. Hyperkalemic periodic paralysis (HYPP [MIM
170500]) (Ptacek et al. 1991), characterized by short,
mild, frequent attacks of profound weakness, beginning
in infancy, provoked by rest after exercise or stress and
often with myotonia between attacks. During an attack,
plasma potassium levels rise to pathological levels, likely
via release from the muscle. HYPP is characteristically
caused by missense mutations in the transmembrane
spans, and some HYPP alleles can additionally produce
malignant hyperthermia (MSH2 [MIM 154275]) (Mos-
lehi et al. 1998). This phenotype is also a component of
Andersen syndrome, discussed above, affecting KCNJ2
(Preisig-Muller et al. 2002).
2. HOKPP (Bulman et al. 1999), characterized by
infrequent, long-lasting, profound, painless episodes of
weakness, beginning in the 2nd decade, provoked by glu-
cose intake or insulin release or upon awakening. During
an attack, the plasma potassium can fall to dangerous
levels, presumably driven into themuscles. Asmentioned
above, two other loci, CACNA1S and KCNE3, also have
alleles that produce this syndrome.
3. Paramyotonia congenita (MIM 168300) (Ptacek
et al. 1992), a cold-exacerbated myotonia.
4. Potassium-activated myotonia (MIM 603967
.0012) (McClatchey et al. 1992), an unusual form of
myotonia.
The essential biophysical feature of the sodium channel
that makes the broad range of phenotypes mentioned
above interpretable is the fact that, although a depo-
larization will make it more probable that the voltage-
sensitive gate of the closed channel will open, when
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sustained, depolarization also leaves behind more of the
channels in an “inactive” nonexcitable conformation.
Because the sodium channel is the major mechanism for
propagating action potentials in all types of neurons
and muscles, this delicate balancing act has the potential
to move these tissues from a state of hyperexcitability
to a state of inexcitability. This feature also explains why
one sees profound muscle weakness with the SCCMS
congenital myasthenia-acetylcholine–receptormutations.
One might guess that the prolonged receptor activation
the mutant alleles produce will give a hyperexcitable
muscle; however, the phenotype seen is produced by the
loss of sodium channels into the inactive state in the
chronically depolarized tissue, rendering themuscle inex-
citable and, therefore, weak. It is likely that this feature
of the sodium channel will play an important role in
understanding phenotypes in the CNS and other tissues
as well.
The CNS Phenotypes: Seizures, Ataxia, and Migraine
Seizures, the major ion-channel phenotype in the CNS,
and one serving as a springboard for considering the
others, is in many ways similar to the arrhythmia phe-
notype in the hyperexcitable LQT heart. It is a periodic
disorder in which the normal rhythmic electrical activity
of the tissue is temporarily lost. In the heart, this may
be a once-in-a-lifetime event. In the CNS, it can be a
lifelong chronic condition, epilepsy. During a seizure, an
abnormally synchronous discharge occurs that produces
stereotyped alterations in behavior. Whereas the heart is
typified by its extremely homogeneous set of responding
cells, the CNS displays maximal tissue complexity, both
in terms of the number of different cell types present
and in the number of different ways they connect with
and influence one another in stimulatory or inhibitory
fashions. Physiologically, global synchrony in the CNS is
actively prevented. Therefore, although one can visualize
the very specific and individual contribution each chan-
nel type makes to components of an action potential
perturbed in LQT or skeletal muscle syndromes, one can
much less specifically interpret how or even where the
channel dysfunction underlying seizures occurs. A sim-
plification of predicted molecular pathology derived
from the cardiac and muscle syndromes, however, is that
K and Cl- channels, which physiologically stabilize ex-
citable tissue, will have pathological lesions that dimin-
ish their current and that Na and Ca channels, which
physiologically excite the tissue, will have gain-of-func-
tion lesions (table 2).
Idiopathic epilepsy is a common polygenic disorder
that affects ∼1% of the population and accounts for
∼40% of all epilepsy. It is overwhelmingly a genetic
disease, with MZ twins 195% concordant for the phe-
notype (Stoffel and Jan 1998). However, most of these
genes still remain to be identified, since only a handful
of rare monogenic epilepsy syndromes are recognized.
Obviously, since ion channels control electrical activity
in the CNS, as in the heart and muscle, they are strong
functional candidates for this disorder and, in fact, are
the first and, in humans, nearly the only proven genetic
causes of epilepsy. Predictably, success to date has come
only for the rare monogenic syndromes, and the focus
here will be on extending these findings to the polygenic
CNS disorders. The monogenic disorders have, how-
ever, been covered in detail in recent reviews (Jentsch
2000; Lerche et al. 2001).
The KCNQ Channel Family
The first rare monogenic seizure syndrome for which the
major etiological geneswere identifiedwasBenign familial
neonatal convulsions (BFNC), a rare autosomal dominant
disorder characterized by a brief period of seizures in the
neonatal period, generally resolving in weeks, but 10%
having persistent adult epilepsy. The BFNC loci were
mapped to chromosomes 20 and 8 (Leppert et al. 1989;
Lewis et al. 1993). The BFNC1 gene (MIM 121200)
was positionally localized within chromosome 20q13.3,
taking advantage of a family with the syndrome and a
microdeletion chromosome (Singh et al. 1998). The in-
terrupted locus contained a promising candidate gene,
KCNQ2, a member of the LQT1 gene family that was
predominantly expressed in neurons. Unlike the LQT1
alleles that demonstrate dominant-negative interactions
in vitro, this first BFNC1 allele was a null, and most
subsequent alleles are simply loss-of-function alleles
(Jentsch 2000). The relevant neuronal currents mediated
by this channel must be so critically tuned that patho-
genic alleles can achieve dominance simply via haploin-
sufficiency. Heterozygous null mice display a milder in-
ducible pharmacogenetic syndrome, showing no basal
seizures but only an increased sensitivity to seizure-in-
ducing drugs (Watanabe et al. 2000). Presumably, the
strain’s polygenic background raises their seizure thresh-
old making them appear much like silent-carrier family
members of the probands with “sporadic” LQT syn-
drome who have disease produced by weak alleles.
Since the KCNQ family had the demonstrated ability
to produce disease, other family member genes were
sought by homology. KCNQ3 was thus identified, and
mapping to chromosome 8q was a tempting candidate
for the second BFNC locus (MIM 120201), a hypothesis
proven by finding loss-of-function alleles segregating in
a family (Charlier et al. 1998). Although both KCNQ
subunits produced channels when expressed in vitro,
neither subunit alone produced a recognizable current.
However, KCNQ2 and KCNQ3 were subsequently rec-
ognized to heteromultimerize to form the “M current,”
a long-sought signature potassium current activated by
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muscarinic acetylcholine receptors (mAChR) (Wang et
al. 1998). Therefore, both their gene-family relationship
and their functional subunit interaction help to explain
the common phenotype that mutations in either gene
produce. The final member of this KCNQ family,
KCNQ5, mapping to chromosome 6q14 (MIM
607357) (Lerche et al. 2000), and the only member
still to be associated with a disease, is expressed in neu-
rons and can also interact with KCNQ3 to produce the
M current, making it an extremely strong functional
candidate disease gene (table 2).
The Nicotinic Acetylcholine Receptor
A locus adjacent to KCNQ2 on chromosome 20q13was
the first ion-channel gene demonstrated to contribute
pathogenic alleles to an epilepsy syndrome. This position
caused some confusion, since, for a time, it was mistak-
enly thought to cause BFNC. The gene, CHRNA4, en-
codes the most abundant neuronal isoform of the major
subunit, a4, of the nAChR. Unlike themAChR, discussed
above, which couples to channel gating via G protein
activation (a G-protein–coupled receptor, GPCR), the
nAChR is itself a ligand-gated nonselective cation chan-
nel, its activation depolarizing the membrane. The het-
eropentameric neuronal receptor/channel is related to
the nAChR in muscle that participates in the phenotype
of SCCMS congenital myasthenia. In nerve, it is com-
posed of two a and three b homologous subunits, each
with four transmembrane a helices. The rare seizure
syndrome, autosomal dominant nocturnal frontal lobe
epilepsy (ADNFLE [MIM 600513]), which produces a
phenotype with brief clusters of frontal seizures that oc-
cur at night, was mapped to this region in a family and
missense alleles identified (Steinlein et al. 1995). To date,
three alleles have been recognized, all altering the chan-
nel pore region and receptor function but having no
obvious common effect on in vitro channel behavior.
More recently, mutations in the most abundant neuronal
b subunit, b2, were also recognized to cause this syn-
drome (MIM 605375) (Phillips et al. 2001), suggesting
that the channel isoform relevant to this phenotype is
an a4b2 pentamer. These missense alleles in CHRNB2,
located on chromosome 1q21, produced the common in
vitro effect of receptor activation, suggesting that some
depolarizing gain of function is likely the mechanism of
dominant pathogenesis, like that found in the SCCMS
muscle pathogenic homologs. The vulnerable cell in the
CNS, the function of which is perturbed by these muta-
tions, however, remains to be defined (Lerche et al. 2001).
Febrile Convulsions
Fever lowers the seizure threshold for everyone such that
at extremely high temperatures seizures will universally
occur (Morimoto et al. 1993). Because fever is also com-
mon, it is not surprising that febrile seizures are by far
the most common polygenic seizure disorder, affecting
3%of childrenworldwide (Wallace et al. 1998).Although
these susceptibility genes have yet to be defined, a rare
Mendelian dominant seizure syndrome that includes feb-
rile seizures promises to point them out. This febrile sei-
zure syndrome additionally evolves to include a variety
of afebrile seizures and is called “generalized epilepsywith
febrile seizures plus” (GEFS [MIM 604233]). It rein-
forces the notion discussed above that the interplay of
multiple ion-channel mechanisms in the generation of a
common physiologically relevant action potential renders
ion-channel diseases natural substrates for observing locus
and allelic heterogeneity and, therefore, likely participants
in polygenic disease. In addition to perhaps paving the
way toward understanding the common polygenic dis-
order, this monogenic seizure disorder is perhaps most
informative in illustrating the complexity in discerning
CNS pathophysiology when the relevant cell type being
perturbed is unknown.
The first locus responsible for GEFS was mapped to
chromosome 19q13.1 in a large family, and a missense
mutation was identified in an auxiliary subunit of the
voltage-gated sodium channel. This subunit, the b1 sub-
unit encoded by the gene SCN1B (MIM 600235), has a
single transmembrane helix and functions only tomodify
the activity of the large a subunit. Subsequently, mu-
tations producing GEFS or closely related syndromes
were identified in two different adjacent neuronal so-
dium-channel a subunit genes, SCN1A (MIM 182389)
and SCN2A (MIM 182390), on chromosome 2q24 (Es-
cayg et al. 2000b; Sugawara et al. 2001; Wallace et al.
2001b). Not until the a1 subunit alleles were coexpres-
sed with their auxiliary b subunits did a reproducible
picture of defective channel inactivation and sustained
sodium current appear (Lossin et al. 2002). This is a
picture similar to that observed with the LQT3 and
HYPP and HOKPP alleles of the gene family members
SCN5A and SCN4A, respectively. As in the heart, most
simply, a persistent sodium-channel current can be
viewed as a gain-of-function dominant lesion that fa-
vors a hyperexcitable state; however, the periodic pa-
ralysis lesions caution that inexcitability through the
inactivation mechanism is also possible.
Recently, however, a rare, very severe dominant seizure
syndrome that is initially associated with febrile seizures
but progresses to a malignant seizure phenotype, called
“severe myoclonic epilepsy of infancy” (SMEI [MIM
607208]), proved to be allelic with GEFS. All of doz-
ens of known alleles were shown to be new mutations
in SCN1A, and their nature (e.g., frameshift, nonsense)
suggests they are predominantly functional nulls (Claes
et al. 2001; Ohmori et al. 2002; Sugawara et al. 2002).
The physiological interpretation of these findings is
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clear; haploinsufficiency for the major subunit of the
sodium channel produces a dominant loss-of-function
severe phenotype in a critically tuned tissue. This would
imply that a 50% reduction in depolarizing current in
the relevant cells, which must produce less activation
of those cells, produces CNS activation and seizures.
One would have to presume that the critical target cells
of this lesion natively have inhibitory silencing activity
in the CNS. This notion, however, makes it tricky to
explain how dominant gain-of-function alleles also pro-
duce a seizure phenotype if they function in the same
tissue. It might be that the two allelic lesions impact
different critical tissues, similar to the recessive and
dominant LQT alleles, in this case, tuned to be more
sensitive to losses or gains, respectively, in sodium cur-
rent. In this fashion, the null is sufficient to shut off the
inhibitory cell type, producing global hyperexcitability,
and the gain-of-function GEFS phenotype arises from
intrinsic hyperexcitability in a different cell type.
The remaining GEFS locus recognized to date per-
haps gives further clues as to the nature of the hypo-
thetical silencing inhibitory critical cells hinted at by the
SMEI alleles. This gene,GABRG2 (MIM137164), found
within a cluster of GABA receptor genes on chromo-
some 5q31, encodes the g2 subunit of the inhibitory
GABAA receptor (Baulac et al. 2001; Wallace et al.
2001a). Very recently, one of the other members in this
receptor gene cluster—GABRA1, encoding the a1 sub-
unit of the receptor—was recognized to carry a missense
mutation segregating in a family with juvenile myo-
clonus epilepsy (JME [MIM 606904]) (Cossette et al.
2002). It is not unreasonable to consider these two sei-
zure syndromes together, since, of the 17 distinct GA-
BAA subunits recognized, the a1 and g2 (together with
the b2) subunits are a preferred combination and the
most widely coexpressed in the brain (Rabow et al.
1995). The GABAA receptor, like the nAChR discussed
above, is a pentameric ligand-gated channel, but it dif-
fers in that, instead of conducting a depolarizing cati-
onic current, it conducts a stabilizing chloride current.
This receptor is the major mechanism through which
GABA, the principle inhibitory neurotransmitter in the
brain, functions (Hevers and Luddens 1998). It is at this
site that the benzodiazepine class of seizure medications
act to potentiate GABA effects and seizure inducers,
such as picrotoxin, act to inhibit GABA (Hevers and
Luddens 1998). So, physiologically, the inhibitory, neu-
ronal silencing activity of GABA participates in pre-
venting seizures. The GEFS allele produces a decrease
in GABA-induced chloride current in vitro (Baulac et
al. 2001), as does the JME allele (Cossette et al. 2002).
Therefore, like the seizure-inducing drugs, seizure-in-
ducing mutations in both loci alter receptor/channel
function to produce less GABA-induced stabilizing cur-
rent. GABA primarily acts to prevent the spread, not
the initiation, of a seizure discharge, so the cells on
which it functions may be the same as those activated
by the gain-of-function sodium-channel GEFS alleles,
giving all the alleles that produce GEFS a common
target and common effect on membrane potential. Per-
haps the inhibitory cells silenced by haploinsufficiency
in SMEI are those cells with the physiological role of
releasing the GABA; perhaps they are inhibitory inter-
neurons, again producing the same postsynaptic effect
in the recipient cells as the GEFS alleles.
Other CNS Ion-Channel Phenotypes: Of Mice and
Men
Although some human “seizure” genes have not recapit-
ulated that phenotype in mice (for instance, mice homo-
zygous for null alleles of CHRN4A and CHRNB2, the
two loci thus far recognized with alleles causing ADN-
FLE in humans, have a phenotype that alters the pain
response, not seizures [Marubio et al. 1999]), sponta-
neous mutations producing a seizure phenotype in mice
have led to the recognition of an important new category
of ion-channel seizure disorders in humans, those alter-
ing voltage-gated calcium-channel function (Meisler et
al. 2001). More importantly, those loci have proven to
be particularly informative for their ability to tie the
various neurological phenotypes together in an inter-
pretable fashion. As discussed above, the voltage-gated
calcium channels are similar to the voltage-gated sodium
channel, and the major pore-containing a1 subunit that
dictates the channel’s subtype is pseudotetrameric, with
a function modified by the auxiliary b, g, and a2/d sub-
units. Alleles in all four different types of neuronal volt-
age-gated calcium-channel subunit genes produce a
monogenic absence seizure phenotype in mice. The “le-
thargic,” “stargazer,” and “ducky” mice are recessive
phenotypes produced by mutations altering neuronal
calcium-channel auxiliary subunits, CACNB4 encoding
a b subunit (Burgess et al. 1997), CACNG2 encoding a
g subunit (Letts et al. 1998), and CACNA2D2 encoding
a protein cleaved to produce the a2 and d subunit (Bar-
clay et al. 2001), respectively. Of these three genes, a
human phenotype has been reported only for mutations
in the first. The human CACNB4 gene maps to human
chromosome 2q22-q23, and two dominant alleles, a
truncation and missense allele, were found in families
with a dominant seizure syndrome (MIM 601949) (Es-
cayg et al. 2000a). The human CACNG2 maps to chro-
mosome 22q13.1 and the human CACNA2D2 gene to
3p21.3, both remaining only promising seizure candidate
genes in humans. The “tottering” and “leaner” mice are
recessive phenotypes produced by alleles of CACNA1A,
the gene encoding the major a1 subunit of the neuronal
P/Q-type calcium channel (Fletcher et al. 1996). The P/
Q-type calcium channel plays a major role in calcium
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entry underlying synaptic release of the major excitatory
neurotransmitter, glutamate, and, although this process
is decreased in the mutants, suggesting they are hypo-
morphic alleles, it is unclear how this produces a hyper-
excitable seizure phenotype (Caddick et al. 1999). Per-
haps the critical target cells are themselves inhibitory, as
suggested above for SMEI. Although these mice have
a seizure phenotype, this is not the major phenotype
caused by mutations in this gene in humans. Human
mutations in CACNA1A, which maps to chromosome
19p13, have been shown to cause three apparently dis-
tinct and different late-onset neurological disease phe-
notypes: episodic ataxia type 2 (EA2 [MIM 108500])
(Ophoff et al. 1996), familial hemiplegic migraine type
1 (FHM1 [MIM 141500]) (Ophoff et al. 1996), and
spinocerebellar ataxia type 6 (SCA6 [MIM 183086])
(Zhuchenko et al. 1997). The EA2 alleles are predom-
inantly truncations, with 122 known alleles, including
frameshift and splice-site mutations, but there are also
five missense alleles, some of which alter conserved pore
residues producing complete loss of function (Van Den
Maagdenberg et al. 2002). It is, therefore, presumably a
haploinsufficiency dominant loss-of-function syndrome.
FHM is caused by at least nine known missense alleles,
producing no obvious uniform functional change in cal-
cium current in vitro; therefore, the relevant functional
change they share in common is presumably subtle (Kors
et al. 2002). Finally, SCA6 is a progressive degenerative
phenotype primarily caused by trinucleotide expansion
alleles. The polymorphic CAG repeat encodes a C-ter-
minal polyglutamine repeat of 5–20 residues in unaf-
fected individuals. Pathogenic alleles encode 21–30 glu-
tamines (Ishikawa et al. 1997; Zhuchenko et al. 1997).
The only point mutant allele recognized as producing
the syndrome is G293R, which changes a conserved pore
residue (Yue et al. 1997). An intermediate-length CAG-
repeat allele with only 20 repeats produced the milder
phenotype of EA2 (Jodice et al. 1997).
Thus, the four allelic CACNA1A diseases in human
and mouse are clearly closely related at the molecular
level. The phenotypes also can blend one into the other;
for instance, many individuals with FHM have ataxia,
as do most of the murine seizure mutants (Ducros et al.
2001; Zwingman et al. 2001), and, recently, a domi-
nant-negative truncation allele has been reported to pro-
duce a syndrome of progressive ataxia and seizures in
a child (Jouvenceau et al. 2001). In humans, the mildest
alleles appear to be the missense mutations that produce
FHM1. On a phenotypic continuum, these appear to be
hypomorphic, since the truncations, pore mutations, and
intermediate repeat expansions produce EA2, appar-
ently a haploinsufficiency syndrome. Expanding the po-
lyglutamine repeat by only a few additional residues
yields the potent long-repeat alleles producing the pro-
gressive SCA6 syndrome, which can also be produced
by one specific missense pore mutation. Although the
mechanism of action of all pathogenic polyglutamine
expansion alleles is controversial, if the three human
CACNA1A phenotypes are truly the continuum sug-
gested by the EA2 intermediate-repeat phenotype, these
repeat expansion alleles should be dominant negative
to eliminate more of the P/Q current than haploinsuf-
ficiency and to keep the progression of allele potency
parallel to the severity of the symptoms and pathology.
Although all of the human alleles produce the pheno-
type in heterozygotes, the mouse seizure alleles, which
are missense, like FHM1, and demonstrated to be hypo-
morphic, produce no phenotype in heterozygotes, in-
cluding knockout null alleles (Jun et al. 1999); decreased
synaptic glutamate neurotransmitter release and seizures
are produced only in the homozygotes.
On the basis of only one clear human case (Jouvenceau
et al. 2001), is it clear that the phenotypes of FHM, EA,
and SCA reflect a pathophysiology similar to that of
seizures, a phenotype only reproducibly seen in mice?
That the seizure phenotype in humans and mice is
caused by mutations in calcium-channel auxiliary sub-
units (Escayg et al. 2000a) reinforces this notion, but
perhaps the best clue comes from the other known epi-
sodic ataxia locus,EA1 (MIM 160120). EA1 is produced
by dominant loss-of-function alleles of perhaps themost
“famous” potassium channel, “shaker” (Browne et al.
1994), named after its mutant phenotype in fly, and the
paradigmatic first K channel cloned (Tempel et al.
1987). It is a voltage-gated potassium channel formally
called KCNA1. Knockout null alleles in the mouse pro-
duce a recessive seizure disorder, with the heterozygotes
lacking a phenotype just like the calcium-channel mu-
tants but, like them, showing a reduced seizure threshold
(Smart et al. 1998; Rho et al. 1999). Although the vast
majority of patients with EA1 have only ataxia, a few
individuals have been reported to have seizures also (Zu-
beri et al. 1999; Eunson et al. 2000). It remains to be
determined if the mice “shaker” mutants, like the cal-
cium-channel mutants, have decreased synaptic gluta-
mate release; however, it is intriguing that the homozy-
gous KCNA1 nulls have enhanced pain sensitivity (Clark
and Tempel 1998), like the CHRN4A and CHRNB2
nulls that failed to emulate the human ADNFLE seizure
phenotype, mentioned above.
The Prospects of Polygenic CNS Ion-Channel
Syndromes
Although it is obvious to consider the CNS ion-channel
genes that were found above to produce the four cardinal
related monogenic phenotypes as candidates for carrying
the mutations and polymorphisms that will produce the
much more common polygenic forms of the seizure,
ataxia, or migraine syndromes, there are two major
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questions to consider for the future. First, do these car-
dinal syndromes reflect the full range of polygenic CNS
ion-channel phenotypes? Second, if we assume that
rare monogenic syndromes do not directly demonstrate
all of the critical ion channel participants in polygenic
disease, from what has been learned of the pathogenic
alleles in the monogenic syndromes, what are reasonable
features to expect them to possess that would warrant
candidate status?
First, it is likely that polygenic ion-channel disorders
produce a wider range of phenotypes than those already
revealed by the monogenic disorders. The salient feature
of the CNS ion-channel disorders, as well as those in the
heart and muscle, was that they arose from a periodic
disturbance in normal rhythmic activity. They were in-
trinsically episodic disorders, althoughmany progressed
to become constant. Many of the common complex
polygenic neuropsychiatric disorders share this char-
acter. Further, several of the drugs used to treat the
recognized channel phenotypes are additionally used to
treat these disorders (e.g., valproate is used to treat both
seizures and bipolar disease). In that field, an enormous
amount of attention has already focused on the neuro-
transmitter/neuroreceptor genes as functional candi-
dates. They seem obvious candidates, since the phar-
macology used to treat or to phenocopy these disorders
typically targets those mechanisms. On the other hand,
ion channels are perhaps more compelling candidates
(Gargus et al. 1998). Themonogenic disorders discussed
above illustrate how ion-channel and neuroreceptor/
channel mutants produce a common, shared disease
phenotype (e.g., GEFS alleles of sodium channel and
GABAA receptor genes). Moreover, they illustrate that
essentially the only reason nature “bothers” to activate
a neuroreceptor is to trigger a response from the ion
channels sharing its membrane. Further, the channels
reflect a tissue selectivity not achievable by the much
more ubiquitously utilized limited repertoire of recep-
tors; that is the very reason drugs targeting them are so
prone to side effects and, perhaps, the reason so many
receptor classes have yet to be demonstrated to have
any functionally altered pathogenic alleles.
An increasingly important approach to the identifi-
cation of genes underlying polygenic disease is to iden-
tify “functional candidates” within broad chromosomal
regions and to test disease association with polymorphic
markers within these candidates. Ion-channel candidates
would be suggested by the known physiology, pharma-
cology, and pathophysiology; their appropriate or ex-
tremely narrow tissue distribution; their membership in
a demonstrably pathogenic gene family; and their con-
tribution to a demonstrably vulnerable component of
the action potential or a salient disease-associated motif
(e.g., a polyglutamine repeat in a disease showing an-
ticipation) (Chandy et al. 1998; Dror et al. 1999). The
existence of alleles sharing features common to patho-
genic alleles underlying the monogenic channelopathies,
such as dominant-negative inhibition of expressed chan-
nel function or incomplete inactivation, would be par-
ticularly suggestive (Miller et al. 2001; Tomita et al., in
press).
For the discovery of a polygenic disease-associated
gene to have full impact in modern medicine, it will be
necessary to understand its function and to find small
molecules able to alter that function, such “rationally
designed” novel pharmaceuticals being one of the major
hopes for the postgenomic era. Although often posi-
tionally identified disease genes have been slow to yield
in both regards, ion channels are highly amenable and
proven targets. Further, as our current pharmacopeia is
overwhelmingly predominated by molecules targeting
receptors (180%), channels represent qualitatively dif-
ferent novel targets. For example, discovering ion-chan-
nel participants in a disease, such as the monogenic
seizure disorders caused by KCNQ2 and KCNQ3 mu-
tations, suggests not only a novel type of target for
therapy (e.g., suggesting use of acetazolamide, a drug
proven effective in a wide range of ion-channel dis-
eases), but also that these channels themselves can fur-
ther serve as the guides to finding entirely novel phar-
maceuticals. Because the function of channelmechanisms
is so well understood, it is clear that the therapeutic
goal will be either a channel blocker or a channel ac-
tivator, and many drugs of both types are already in
current use. In vitro expression assays of channel func-
tion can be used in high-throughput drug screening and
in drug optimization (Shieh et al. 2000). An example
of this kind of breakthrough is retigabine, a novel class
of seizure medication proven to activate the KCNQ2/
KCNQ3 “M current” channel that is suggested as a
seizure drug target by the role of these genes in BFNC
(Wickenden et al. 2000). Since the channel mechanisms
perturbed in such disorders are likely to be critical par-
ticipants in producing the relevant membrane potentials
that lead to a disease vulnerability, the drugs targeting
them should be useful for treating the disease even in
those not having an intrinsic defect in the targetedmech-
anism. Another advantage of pharmacology targeted to
channels is the expectation, discussed above, that a nar-
row range of tissues express the channel in a physio-
logically important context; therefore, drug specificity
is achieved and unwanted side effects are minimized.
Therefore, in this postgenomic world rich in potential
targets, even should ion channels reflect only a minority
of the relevant etiological candidates in polygenic CNS
disease, they may well provide the most rapid access to
novel therapeutics, warranting prioritization for early
evaluation for that reason alone. However, the dem-
onstrated ability of ion channels to cause the wide range
of monogenic CNS phenotypes discussed above suggests
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they will likely be important common participants in
the polygenic CNS diseases as well.
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